Author

O. Komm

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 4 Research Focus:drug response / drug discovery· 3 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

A. A. Ordonez· 2 shared C. K. Bullen· 2 shared D. Almeida· 2 shared E. Nuermberger· 2 shared P. J. Converse· 2 shared S. K. Jain· 2 shared A. F. Villabona-Rueda· 1 shared A. Gupta· 1 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. A. Ordonez

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Dynamic single-cell RNA sequencing reveals BCG vaccination curtails SARS-CoV-2 induced disease severity and lung inflammation

A. K. Singh, R. Wang, K. A. Lombardo, M. Praharaj, C. K. Bullen, P. Um, S. Davis, O. Komm, P. B. Illei, A. A. Ordonez, M. Bahr, J. Huang, A. Gupta, K. J. Psoter, S. K. Jain, , W. Bishai

This study uses single-cell RNA sequencing to show BCG vaccination reduces SARS-CoV-2 lung inflammation and disease severity by enhancing antibody production and altering immune cell transcriptional profiles.

bioRxiv · Mar 15, 2022 · PreprintImmunology

Impact of dose, duration and host immune status on ultrashort telacebec treatment in a mouse model of Buruli ulcer

P. J. Converse, D. Almeida, O. Komm, E. Nuermberger

This study evaluates the efficacy of ultrashort telacebec treatment in mouse models of Buruli ulcer, finding that total dose is more critical than duration and that resistance can emerge in immunocompromised hosts.

bioRxiv · Jun 22, 2021Microbiology

Ultrashort treatment with telacebec alone and with companion drugs in immunocompetent and immunosuppressed mouse footpad models of Buruli ulcer

P. J. Converse, O. Komm, D. Almeida, T. F. Omansen, E. Nuermberger

This study evaluates the efficacy of telacebec alone and with companion drugs in reducing treatment duration for Buruli ulcer in immunocompetent and immunosuppressed mice.

bioRxiv · Jun 22, 2021 · PreprintMicrobiology

Sulforaphane exhibits in vitro and in vivo antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses

A. A. Ordonez, C. K. Bullen, A. F. Villabona-Rueda, E. A. Thompson, M. L. Turner, S. L. Davis, O. Komm, J. D. Powell, F. R. D'Alessio, R. H. Yolken, S. K. Jain, L. Jones-Brando

This study shows sulforaphane inhibits SARS-CoV-2 and HCoV-OC43 replication in vitro and reduces viral load and lung injury in mice.

bioRxiv · Mar 25, 2021Microbiology